Literature DB >> 20019360

Chemotactic and cytotoxic effects of minocycline on human retinal pigment epithelial cells.

Margrit Hollborn1, Peter Wiedemann, Andreas Bringmann, Leon Kohen.   

Abstract

PURPOSE: To reveal the effects of minocycline, an anti-inflammatory and neuroprotective agent, on the viability and physiological properties of retinal pigment epithelial (RPE) cells and to compare the effects with those of triamcinolone acetonide.
METHODS: The proliferation of human RPE cells in vitro was investigated with a bromodeoxyuridine immunoassay; chemotaxis was examined with a Boyden chamber assay. Cell viability was determined by trypan blue exclusion. The gene expression of growth factors and MMP-9 was determined with real-time RT-PCR, and the secretion of VEGF was examined with ELISA. The phosphorylation of p38 MAPK and ERK1/2 proteins was determined with Western blot analysis.
RESULTS: Minocycline at low concentrations (50 nM-20 microM) stimulated chemotaxis and decreased the proliferation of RPE cells. Minocycline at high concentrations (above 5 microM) decreased the viability of RPE cells through the induction of cell necrosis. The chemotactic effect of minocycline was mediated by the stimulation of autocrine PDGF signaling and the activation of p38 MAPK. Minocycline promoted the expression of PDGF-B, HGF, VEGF, and MMP-9 and increased the amounts of phosphorylated p38 and ERK1/2 proteins in RPE cells. Triamcinolone reduced PDGF-evoked chemotaxis and VEGF expression and secretion and had no significant effects on cell viability and proliferation. Triamcinolone did not reverse the effects of minocycline on cell proliferation, chemotaxis, or viability or the expression of VEGF.
CONCLUSIONS: Low-dose minocycline induces the activation of RPE cells, as indicated by the activation of p38 and ERK1/2 and by enhanced chemotaxis mediated by autocrine PDGF signaling. High-dose minocycline induces RPE cell degeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019360     DOI: 10.1167/iovs.09-4661

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Minocycline reduces oxygen-glucose deprivation-induced PC12 cell cytotoxicity via matrix metalloproteinase-9, integrin β1 and phosphorylated Akt modulation.

Authors:  Xiaohong Chen; Shaoqiong Chen; Ying Jiang; Cansheng Zhu; Aimin Wu; Xiaomeng Ma; Fuhua Peng; Lili Ma; Dongliang Zhu; Qing Wang; Rongbiao Pi
Journal:  Neurol Sci       Date:  2012-12-07       Impact factor: 3.307

Review 2.  Can tetracyclines ensure help in multiple sclerosis immunotherapy?

Authors:  Pedro Víctor-Carvalho; Rodolfo Thome; Catarina Rapôso
Journal:  J Clin Transl Res       Date:  2021-02-03

3.  Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice.

Authors:  Yun Hou; Chung Heon Ryu; Kwang Ywel Park; Seong Muk Kim; Chang Hyun Jeong; Sin-Soo Jeun
Journal:  Stem Cell Res Ther       Date:  2013-07-05       Impact factor: 6.832

4.  Chorionic gonadotropin and its receptor are both expressed in human retina, possible implications in normal and pathological conditions.

Authors:  Sladjana Dukic-Stefanovic; Jan Walther; Sebastian Wosch; Gerolf Zimmermann; Peter Wiedemann; Henry Alexander; Thomas Claudepierre
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

5.  Efficient photodynamic therapy on human retinoblastoma cell lines.

Authors:  Jan Walther; Stanislas Schastak; Sladjana Dukic-Stefanovic; Peter Wiedemann; Jochen Neuhaus; Thomas Claudepierre
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

6.  Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells.

Authors:  Rui Chen; Margrit Hollborn; Antje Grosche; Andreas Reichenbach; Peter Wiedemann; Andreas Bringmann; Leon Kohen
Journal:  Mol Vis       Date:  2014-03-03       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.